Onno van de Stolpe obtained an MSc degree from the Agricultural University in Wageningen (WUR) in the Netherlands. He started his career as Manager Business Development at MOGEN in Leiden, before joining the Netherlands Foreign Investment Agency in California.
After he returned to The Netherlands in 1995, Onno set up the European operations for Molecular Probes in Leiden. In 1998, he was cofounder of Galapagos. Over a period of 24 years, he grew Galapagos as its CEO to one of the largest biotech companies in Europe and brought Jyseleca, a drug for inflammatory disease, to the market. In 2022 he left the company and he currently serves on the boards of Protix, Leyden Labs, BioCann and Stichting African Parks Foundation.
